NIDDK Central Repository - The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.1053/j.gastro.2010.10.047

PubMed ID

21036173

Public Release Type

Journal

Publication Year

2011

Affiliation

Department of Pediatrics, Division of Gastroenterology and Nutrition, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. kschwarz@jhmi.edu

Authors

Balistreri WF, Barton BA, Gonzalez-Peralta RP, Goodman Z, Haber BA, Jonas MM, Lobritto SJ, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Peds-C Clinical Research Network, Robuck PR, Rosenthal P, Rossi S, Schwarz KB, Smith L, Valsamakis A

Studies

PEDS-C

Citation

Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA, Peds-C Clinical Research Network. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011 Feb;140(2):450-458.e1. Epub 2010 Oct 28.

Abstract

Although randomized trials of adults infected with hepatitis C virus (HCV) have shown that ribavirin increases the efficacy of pegylated interferon (PEG), such trials have not been performed in children. We conducted a randomized controlled trial of PEG and ribavirin, compared with PEG and placebo, in children 5 to 17 years old with chronic hepatitis C.